Luca Cantini1, Federica Pecci2, Daan P Hurkmans3, Robert A Belderbos3, Andrea Lanese2, Cecilia Copparoni2, Sophie Aerts3, Robin Cornelissen3, Daphne W Dumoulin3, Ilaria Fiordoliva2, Silvia Rinaldi2, Joachim G J V Aerts3, Rossana Berardi4. 1. Clinical Oncology, Università Politecnica Delle Marche, AOU Ospedali Riuniti Ancona, Italy; Department of Pulmonary Medicine, Erasmus MC Rotterdam, the Netherlands; Erasmus MC Cancer Institute, Erasmus MC Rotterdam, the Netherlands. 2. Clinical Oncology, Università Politecnica Delle Marche, AOU Ospedali Riuniti Ancona, Italy. 3. Department of Pulmonary Medicine, Erasmus MC Rotterdam, the Netherlands; Erasmus MC Cancer Institute, Erasmus MC Rotterdam, the Netherlands. 4. Clinical Oncology, Università Politecnica Delle Marche, AOU Ospedali Riuniti Ancona, Italy. Electronic address: r.berardi@staff.univpm.it.
Abstract
BACKGROUND: In preclinical models, statins showed vaccine adjuvant activities and synergized with PD-1 inhibitors. We analyzed the impact of statin treatment on clinical outcome in thoracic cancer patients treated with PD-1 inhibitors. METHODS: A total of 82 malignant pleural mesothelioma (MPM) and 179 advanced non-small cell lung cancer (aNSCLC) patients treated with PD-1 inhibitors as second or further line treatment were examined. Seventy-seven MPM patients treated with standard chemotherapy were analyzed as control cohort. Objective response rate (ORR), progression-free survival (PFS), and overall survival (OS) were calculated. RESULTS: Among 253 patients with available data, statin use was associated with increased ORR (32% versus 18%, P = .02), PFS (median 6.7 versus 2.9 months, hazard ratio [HR] 0.57, 95% CI 0.39-0.83, P < .01), and OS (median 13.1 versus 8.7 months, HR 0.67, 95% CI 0.45-1.00, P = .05). In the control MPM cohort treated with chemotherapy (n = 77), no association was found. MPM patients who used statins showed improved ORR (22% versus 6%, P = .05), PFS (median 6.7 versus 2.4 months, P < .01), and OS (median not reached versus 6.0 months, P = .01). In aNSCLC patients, statin use was associated with improved ORR (40% versus 22%, P = .04) and PFS (median 7.8 versus 3.6 months, P = .03), but no significant difference in OS was found (median 13.1 versus 10.1 months, P = .30). Multivariable analysis confirmed the correlation between statin use and better PFS and OS in MPM and better PFS in aNSCLC. In the whole cohort, high but not low/moderate-intensity statins were associated with better OS compared to no user (P = .02 and P = .59, respectively). CONCLUSIONS: Our study showed that statins are associated with better clinical outcome in MPM and aNSCLC patients treated with PD-1 inhibitors in an intensity-dependent manner.
BACKGROUND: In preclinical models, statins showed vaccine adjuvant activities and synergized with PD-1 inhibitors. We analyzed the impact of statin treatment on clinical outcome in thoracic cancerpatients treated with PD-1 inhibitors. METHODS: A total of 82 malignant pleural mesothelioma (MPM) and 179 advanced non-small cell lung cancer (aNSCLC) patients treated with PD-1 inhibitors as second or further line treatment were examined. Seventy-seven MPM patients treated with standard chemotherapy were analyzed as control cohort. Objective response rate (ORR), progression-free survival (PFS), and overall survival (OS) were calculated. RESULTS: Among 253 patients with available data, statin use was associated with increased ORR (32% versus 18%, P = .02), PFS (median 6.7 versus 2.9 months, hazard ratio [HR] 0.57, 95% CI 0.39-0.83, P < .01), and OS (median 13.1 versus 8.7 months, HR 0.67, 95% CI 0.45-1.00, P = .05). In the control MPM cohort treated with chemotherapy (n = 77), no association was found. MPM patients who used statins showed improved ORR (22% versus 6%, P = .05), PFS (median 6.7 versus 2.4 months, P < .01), and OS (median not reached versus 6.0 months, P = .01). In aNSCLC patients, statin use was associated with improved ORR (40% versus 22%, P = .04) and PFS (median 7.8 versus 3.6 months, P = .03), but no significant difference in OS was found (median 13.1 versus 10.1 months, P = .30). Multivariable analysis confirmed the correlation between statin use and better PFS and OS in MPM and better PFS in aNSCLC. In the whole cohort, high but not low/moderate-intensity statins were associated with better OS compared to no user (P = .02 and P = .59, respectively). CONCLUSIONS: Our study showed that statins are associated with better clinical outcome in MPM and aNSCLC patients treated with PD-1 inhibitors in an intensity-dependent manner.
Authors: Jacqueline T Vuong; Ashley F Stein-Merlob; Arash Nayeri; Tamer Sallam; Tomas G Neilan; Eric H Yang Journal: J Am Coll Cardiol Date: 2022-02-15 Impact factor: 24.094
Authors: Alessio Cortellini; Massimo Di Maio; Olga Nigro; Alessandro Leonetti; Diego L Cortinovis; Joachim Gjv Aerts; Giorgia Guaitoli; Fausto Barbieri; Raffaele Giusti; Miriam G Ferrara; Emilio Bria; Ettore D'Argento; Francesco Grossi; Erika Rijavec; Annalisa Guida; Rossana Berardi; Mariangela Torniai; Vincenzo Sforza; Carlo Genova; Francesca Mazzoni; Marina Chiara Garassino; Alessandro De Toma; Diego Signorelli; Alain Gelibter; Marco Siringo; Paolo Marchetti; Marianna Macerelli; Francesca Rastelli; Rita Chiari; Danilo Rocco; Luigi Della Gravara; Alessandro Inno; De Tursi Michele; Antonino Grassadonia; Pietro Di Marino; Giovanni Mansueto; Federica Zoratto; Marco Filetti; Daniele Santini; Fabrizio Citarella; Marco Russano; Luca Cantini; Alessandro Tuzi; Paola Bordi; Gabriele Minuti; Lorenza Landi; Serena Ricciardi; Maria R Migliorino; Francesco Passiglia; Paolo Bironzo; Giulio Metro; Vincenzo Adamo; Alessandro Russo; Gian Paolo Spinelli; Giuseppe L Banna; Alex Friedlaender; Alfredo Addeo; Katia Cannita; Corrado Ficorella; Giampiero Porzio; David J Pinato Journal: J Immunother Cancer Date: 2021-04 Impact factor: 13.751